About Us
Recently, Jiangsu MicroDiag announces another breakthrough, creating a new SARS-CoV-2 Rapid Nucleic Acid test kit (LFD), showing promising clinical test results in trials done in Chongqing public health care centers，reaching an outstanding outcome.
This round of tests focuses on patients that have been clinically confirmed with COVID-19, patients have recovered and released from hospitals. They were given nose and throat swabs in order test MicroDiag SARS-CoV-2 Rapid Nucleic Acid test kit for its detection agility, specificity, and overall matching rates.
This round of tests involves 80 samples: 50 positive cases, 30 negative cases. The age spread is between 4-86 years old, median age is 41.5. 43 male samples, 37 female samples, with a male to female ratio of 1.16:1. Among the positive cases, 15 cases are asymptomatic (30%), 25 mild cases (50%),6 average cases (12%), 3 severe cases (6%), 1 critical case (2%). Days of onset symptoms ranges from 2 to 46 days, median being 14.5 days. When divided by different stages of the disease, 9 cases were early stage (18%), 18 cases were middle stage (36%), 23 cases were late stage (46%).
Analysis from results show that MicroDiag SARS-CoV-2 Rapid Nucleic Acid test kit discovered 100% of positive cases in different clinical types, different onset time, different disease stages. In the meantime, the results from this test kit matches perfectly with the results from RT-qPCR tests.
Due to the fantastic performances observed from this round of tests, MicroDiag will work to meet the expectations, in order to accelerate the process to bring this product to the market, and contribute to the front lines against this global pandemic.